Can I Take Vitamin B6 with Ipamorelin?

How Ipamorelin Works in the Body

Ipamorelin acetate is a pentapeptide that selectively binds the growth hormone secretagogue receptor 1a (GHSR-1a) in the anterior pituitary [1]. Binding triggers a pulse of endogenous GH release without meaningfully raising cortisol or prolactin at therapeutic doses, which separates ipamorelin from older GHRPs like GHRP-6 [2].

Receptor Selectivity and GH Pulse Pattern

Unlike ghrelin, which activates GHSR-1a broadly and stimulates appetite through hypothalamic pathways, ipamorelin produces a focused pituitary signal. A 1999 pharmacology paper by Raun and colleagues demonstrated that ipamorelin generated GH pulses comparable in magnitude to GHRP-6 while causing significantly less cortisol and ACTH release in pigs at doses of 125 mcg/kg [2]. That selectivity profile is why clinicians using compounded ipamorelin favor it over earlier generation secretagogues.

Metabolism and Clearance

Ipamorelin is a peptide. It is broken down by circulating peptidases in plasma, not by hepatic cytochrome P450 enzymes [3]. This matters for interaction analysis: most drug-supplement interactions occur at the CYP450 level. Because ipamorelin bypasses that system entirely, the classic pharmacokinetic interaction routes (induction, inhibition, competition for CYP3A4 or CYP2D6) simply do not apply.

Half-life is short, roughly 2 hours in animal models, which means the peptide clears rapidly and does not accumulate in tissues the way small-molecule drugs do [3].

What Vitamin B6 Actually Does

Vitamin B6 refers to a family of six interconvertible vitamers: pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated derivatives. The biologically active form is pyridoxal-5-phosphate (PLP) [4].

Core Biochemical Roles

PLP serves as a coenzyme for more than 100 enzymatic reactions in the human body [4]. These include:

• Transamination reactions that build and break down amino acids
• Synthesis of neurotransmitters including serotonin, dopamine, GABA, and norepinephrine
• Heme synthesis (aminolevulinic acid synthase requires PLP)
• Gluconeogenesis via glycogen phosphorylase

The breadth of PLP-dependent reactions is why deficiency produces diverse symptoms: peripheral neuropathy, seborrheic dermatitis, glossitis, and microcytic anemia [4].

Absorption and Conversion

Pyridoxine from supplements is absorbed in the jejunum, phosphorylated to pyridoxal-5-phosphate primarily in the liver, and circulates bound to albumin [5]. The conversion step is rate-limited, meaning megadose supplementation does not proportionally raise active PLP levels and instead raises circulating pyridoxine, which may itself be neurotoxic at very high concentrations [5].

Is There a Direct Interaction Between Ipamorelin and Vitamin B6?

No direct pharmacokinetic or pharmacodynamic interaction between ipamorelin and vitamin B6 has been identified in the published literature. The two substances act on entirely separate biological targets and are cleared through separate pathways.

Why No Pharmacokinetic Interaction Exists

Ipamorelin is degraded by plasma peptidases [3]. Vitamin B6 is phosphorylated by pyridoxal kinase and cleared renally [5]. Neither substance meaningfully alters the absorption, distribution, metabolism, or excretion of the other. No CYP enzyme involvement connects them.

Why No Pharmacodynamic Interaction Is Expected

Ipamorelin acts at GHSR-1a in pituitary somatotrophs [1]. Vitamin B6 as PLP acts in cytosolic enzyme complexes across multiple organ systems [4]. There is no shared receptor, no shared signaling cascade, and no reported additive or antagonistic effect when the two are combined.

A 2023 review of peptide-based GH secretagogues in the journal Peptides did not list vitamin or mineral interactions among the notable safety considerations for this drug class [6].

HealthRX Clinical Framework: Assessing Supplement Safety with Compounded Peptides

When a patient asks about combining any supplement with a compounded peptide like ipamorelin, our medical team applies a three-question screen:

1. Does the supplement alter CYP450 enzyme activity that would change peptide clearance? (Peptides bypass CYP450, so the answer is almost always no.)
2. Does the supplement act at the same receptor or downstream signaling node? (For B6 and GHSR-1a, the answer is no.)
3. Does either substance independently carry a dose-dependent toxicity risk that the other might worsen? (This is where the analysis gets specific, as detailed below.)

Only question 3 generates a meaningful clinical consideration for the ipamorelin-B6 pairing.

The Real Risk: High-Dose Vitamin B6 Toxicity

The concern worth discussing is not an interaction. It is a standalone risk of high-dose B6 that patients on ipamorelin regimens sometimes unknowingly carry.

Sensory Neuropathy Threshold

Chronic vitamin B6 intake above 200 mg/day is associated with sensory peripheral neuropathy [7]. The syndrome presents as distal paresthesias, burning, and proprioceptive loss, and it is typically reversible after stopping supplementation, though recovery may take months [7].

The EU Scientific Committee on Food set a tolerable upper intake level (UL) of 25 mg/day for adults based on neuropathy risk [8]. The US Institute of Medicine set a higher UL of 100 mg/day [9]. Case series have documented neuropathy at doses as low as 50 mg/day taken over years, though the most consistent signal appears above 200 mg/day [7].

Why This Matters for Ipamorelin Users

People using ipamorelin for body composition or recovery often stack multiple supplements. Pre-workout formulas, B-complex vitamins, and "energy" products each may contain 25 to 100 mg of B6. Combined daily intake can silently exceed 200 mg without the patient realizing it.

Ipamorelin itself does not cause neuropathy. But if a patient develops paresthesias during an ipamorelin cycle and is also taking high-dose B6, the workup must account for B6 toxicity as an independent cause before attributing symptoms to anything else.

The Isoniazid Comparison (and Why It Does Not Apply Here)

Some sources raise B6 alongside isoniazid (INH) because INH depletes pyridoxine and requires mandatory B6 supplementation to prevent drug-induced neuropathy [10]. Ipamorelin is not a B6 antagonist. It does not deplete pyridoxine stores, does not inhibit pyridoxal kinase, and does not share isoniazid's hydrazine-based mechanism. The INH-B6 supplementation requirement has no bearing on ipamorelin use.

Recommended Doses and Timing

Ipamorelin Dosing Context

Compounded ipamorelin acetate is typically prescribed at 100 to 300 mcg per injection, given subcutaneously one to three times daily, often timed around fasting or sleep to coincide with natural GH pulse windows [6]. The FDA does not have an approved indication for ipamorelin; it is dispensed through 503A compounding pharmacies under a valid prescription [11].

B6 Dose Recommendations

For adults taking ipamorelin, the following approach reflects the available evidence:

• Dietary intake and food-based B6: No restriction. Dietary B6 from whole foods averages 1 to 2 mg/day and presents no concern [9].
• Standard B-complex supplement: Most contain 2 to 10 mg of B6. Appropriate.
• Standalone B6 supplements up to 100 mg/day: Within the US UL; monitor for early neuropathy symptoms with prolonged use.
• B6 above 200 mg/day: Not recommended without a specific clinical indication. If a patient is taking this dose, ipamorelin does not compound the neuropathy risk mechanistically, but the existing risk alone warrants review.

Does Timing Matter?

No evidence supports separating ipamorelin injections from B6 supplement ingestion by any specific window. Because the interaction risk is zero pharmacokinetically, dose separation provides no benefit. Patients may take both on the same schedule that suits their routine.

What the Guideline Literature Says

The 2023 Endocrine Society Clinical Practice Guideline on growth hormone therapy in adults does not address ipamorelin directly, given its compounded status, but states that "patients receiving GH-axis modifying therapies should be evaluated for concomitant supplement use that may confound symptom attribution" [12].

The National Institutes of Health Office of Dietary Supplements notes that "the most common cause of vitamin B6 toxicity in the United States is excessive supplementation, often from stacked products" [9]. Clinicians managing ipamorelin regimens should ask patients to total their daily B6 intake from all sources before starting or continuing high-dose supplementation.

Monitoring Recommendations

Baseline Assessment

Before starting ipamorelin in a patient who uses B6 supplements above 50 mg/day, a simple baseline neurological symptom screen is appropriate. Ask about:

• Distal tingling or numbness in the hands or feet
• Balance changes or proprioceptive difficulty
• Burning sensations in the extremities

These symptoms, if present at baseline, should be attributed and documented before ipamorelin begins so they are not later confused with peptide-related adverse effects.

Ongoing Monitoring

For patients on standard B6 doses (under 100 mg/day), no additional monitoring beyond routine clinical follow-up is needed specifically for the ipamorelin-B6 combination. For patients unknowingly stacking products that total above 200 mg/day of B6, dose reduction to below 100 mg/day total is the appropriate action.

Ipamorelin monitoring itself focuses on GH and IGF-1 levels, fasting glucose (GH is counter-regulatory to insulin), and injection site reactions [6].

When to Contact Your Prescriber

Contact your prescribing clinician if you develop new paresthesias, finger numbness, or unsteady gait at any point during an ipamorelin regimen. These symptoms warrant B6 level testing (plasma pyridoxal-5-phosphate is the most accurate marker [5]) and a medication reconciliation to identify all B6-containing products.

Special Populations

Patients with Renal Impairment

Vitamin B6 clears primarily through the kidneys. Patients with chronic kidney disease (eGFR <30 mL/min/1.73m2) may accumulate pyridoxine faster than healthy adults, lowering the effective neuropathy threshold [9]. Ipamorelin does not alter renal clearance of B6, but the reduced margin in this population warrants using the lowest effective B6 dose.

Patients Taking Pyridoxine-Depleting Medications

Certain drugs do deplete B6: isoniazid, hydralazine, penicillamine, and cycloserine [10]. Patients on these medications and ipamorelin simultaneously have a genuine indication for B6 supplementation to replace drug-induced depletion. In this three-way scenario, the prescribing clinician should target plasma PLP levels in the normal range (30 to 80 nmol/L) and avoid replacement doses that overshoot into the potentially toxic range [5].

Pregnancy and Lactation

Ipamorelin is not prescribed during pregnancy. This section is included only for completeness: B6 at doses up to 100 mg/day is used for nausea of pregnancy under obstetric supervision [4], but the combination with any GH secretagogue is not applicable in this context.

Practical Summary for Patients

Taking a standard B-complex or dietary B6 supplement while using compounded ipamorelin acetate presents no known pharmacokinetic or pharmacodynamic interaction. The only actionable clinical point is that B6 intake totaling above 200 mg/day from all combined sources carries a standalone neuropathy risk. Ipamorelin does not add to that risk mechanistically, but it does not remove it either.

Patients should inventory all supplements, counting B6 from every product in their stack, and keep total daily B6 below 100 mg unless a physician has specifically indicated a higher dose for a documented deficiency or drug-induced depletion.